目的:探讨匹伐他汀联合血必净注射液对急性冠脉综合征(Acute coronary syndrome,ACS)病人行PCI术后血清基质金属蛋白酶-9(MMP-9)、五聚素3(PTX 3)水平变化及生活质量的影响.方法:选取2014-12~2017-05期间在我院接受PCI治疗的112例ACS病人,按照随机数字表法分为观察组与对照组各56例.两组PCI术后均行常规治疗,在此基础上,对照组术后给予匹伐他汀治疗,观察组给予匹伐他汀+血必净注射液治疗,两组均连续治疗3mo.对比两组PCI术前及术后3mo血清(MMP-9、PTX 3)水平、生活质量(QOL)评分,统计两组术后3mo内不良心血管事件发生率及用药期间不良反应发生率.结果:(1)血清MMP-9、PTX 3水平:两组血清MMP-9、PTX 3水平PCI术前比较无显著差异(P均>0.05),PCI术后3mo两组血清MMP-9、PTX 3水平均较术前降低(P均<0.05),且观察组血清MMP-9、PTX 3水平均低于对照组(P均<0.05);(2)不良心血管事件发生率:观察组PCI术后3mo内不良心血管事件发生率3.57%(2/56)较对照组14.29%(8/56)低(P<0.05);(3)不良反应:观察组腹痛、倦怠感、皮肤痒感、药疹等不良反应发生率与对照组比较均无显著差异(P均>0.05);(4)生活质量:两组QOL评分 PCI术前比较无显著差异(P>0.05),PCI术后 mo两组 QOL评分均较术前提高(P均<0.05),且观察组QOL评分高于对照组(P<0.05).结论:匹伐他汀联合血必净注射液可有效改善ACS病人PCI术后血清MMP-9、PTX 3水平、降低不良心血管事件发生率,且具有一定安全性,有利于提高病人术后生活质量.%Objective:To investigate the effect of Atorvastatin combined with Xuebijing injection on serum matrix metalloproteinase-9(MMP-9)and poly(five)3(PTX 3)levels and quality of life in pa-tients with acute coronary syndrome(ACS)undergoing PCI.Methods:112 patients with ACS who re-ceived PCI treatment in our hospital from December 2014 to May 2017 were randomly divided into the observation group and the control group with 56 cases in each group.Based on two groups of patients treated with conventional treatment after PCI,the control group was given atorvastatin treatment,and the observation group was given atorvastatin+Xuebijing injection treatment.The two groups were treated for 3months.The serum levels of PCI(MMP-9),PTX 3 and quality of life(QOL)were compared between the two groups before and 3months after PCI operation.The incidence of adverse cardiovascular events and the incidence of adverse drug reactions during the 3months after operation in the two groups were counted.Results:(1)Serum MMP-9 and PTX 3 levels:there was insignificant difference in serum levels of MMP-9 and PTX 3 between the two groups before PCI(P>0.05).3months after PCI,the lev-els of serum MMP-9 and PTX 3 in two groups were lower than those before operation(P＜0.05).And the serum levels of MMP-9 and PTX 3 in the observation group were lower than those in the control group(P＜0.05).(2)The incidence of adverse cardiovascular events:the incidence of adverse cardio-vascular events within 3months after PCI in the observation group was 3.57%(2/56),which was lower than that of the control group 14.29%(8/56)(P＜0.05).(3)Adverse reactions:there was insignificant difference in the incidence of adverse reactions such as abdominal pain,lassitude,skin itching and drug eruption between the observation group and the control group(P>0.05).(4)Quality of life:there was insignificant difference in QOL score between the two groups before PCI(P>0.05),and the QOL scores of the two groups after 3months of PCI were higher than those before the operation(P＜0.05),and the QOL score of the observation group was higher than that of the control group(P＜0.05).Conclusion:Atorvastatin combined with Xuebijing injection can effectively improve the ACS after PCI in patients with serum MMP-9 and PTX 3 levels,reduce the incidence of adverse cardiovascular events,and it has a certain safety.It's conducive to improve the quality of life of patients after operation.
展开▼
机译：EficáciadaN-butilescopolamina edipironasódicapomiadasao cetoprofenonoalíviodadorpós-operatóriadepacientes submetidas aduastécnicasdifrentesde laqueadura por laparoscopia Eficacia de la N-butilescopolamina ydipironasódicaasociadasal cetoprofeno en el alivio del dolor pos-operatorio de腹腔镜腹腔镜手术治疗腹腔镜消毒术后患者术后疼痛缓解的N-丁基东莨菪碱和酮二萜钠与酮洛芬联合应用的疗效观察及腹腔镜手术疗效观察
